Head-to-head comparison
| Property | Dihexa | Semax |
|---|---|---|
| Category | Cognitive | Cognitive |
| Legal Status | Research Only | Research Only |
| Primary Route | oral | nasal |
| Half-life | ~2-6 hours (estimated from animal data) | ~2-3 minutes (rapid enzymatic degradation, but downstream effects persist) |
| Mol. Weight | 507.63 Da | 813.93 Da |
| Side Effects | Limited human safety data, Headache (reported), Anxiety (at higher doses) | Nasal irritation, Headache (rare), Dizziness (rare) |
Key differences
- Potency: Dihexa is reported to be active at picomolar concentrations, potentially millions of times more potent than BDNF on a molar basis; semax is dosed at micrograms.
- Mechanism: Dihexa binds to HGF and potentiates its signaling through the c-Met receptor for synaptogenesis; semax modulates the melanocortin system and upregulates BDNF.
- Clinical evidence: Semax is an approved prescription medication in Russia with published clinical studies; dihexa has only preclinical (animal) data with no human clinical trials.
- Safety data: Semax has decades of clinical use in Russia with an established safety profile; dihexa has minimal safety data and its extreme potency raises theoretical concerns about unintended tissue effects.
- Administration: Dihexa is typically administered subcutaneously or intranasally; semax is primarily administered as a nasal spray.
- Research maturity: Semax has extensive published research from multiple groups; dihexa is based primarily on research from a single laboratory (Harding/Wright at Washington State University).
- Neurotrophic target: Dihexa promotes new synapse formation via HGF/c-Met; semax supports existing neural health and plasticity via BDNF.
The verdict
Semax is the safer, more established option with decades of clinical use and prescription drug status in Russia. Dihexa is the more potent and novel compound with extraordinary preclinical data, but its lack of human clinical trials and safety data makes it a higher-risk choice. For evidence-based nootropic use, semax is the established standard. Dihexa is of interest for researchers willing to accept the uncertainty of a compound with minimal human safety data and extreme potency.
Frequently asked questions
Dihexa has minimal published safety data — only preclinical animal studies. Its extraordinary potency (active at picomolar concentrations) raises theoretical concerns about unintended effects in non-neural tissues where HGF/c-Met signaling is active (including some cancers). No human safety trials have been conducted. Semax, by contrast, has decades of clinical safety data.
Dihexa is active at picomolar concentrations, making it orders of magnitude more potent than most nootropic peptides. Semax is dosed at hundreds of micrograms. However, potency does not equal safety or superiority — dihexa's extreme potency is precisely what makes its safety profile a concern.
They work through different neurotrophic pathways (HGF/c-Met vs BDNF/melanocortin). Some experimental protocols discuss combining them. However, given dihexa's limited safety data and extreme potency, conservative approaches generally recommend established compounds like semax first.
Animal studies suggest dihexa may produce stronger memory effects, potentially reversing cognitive deficits in animal models of dementia. Semax has published human data supporting cognitive improvement. For evidence-based memory support, semax is more established. Dihexa's potential is higher but unvalidated in humans.
No, dihexa is not approved as a medication in any country. It is available only as a research compound. Semax is an approved prescription medication in Russia for stroke recovery and cognitive enhancement.